Hillo Reviews

Hillo Description

To integrate with your diabetes management platform, plug'n play API. Personalized therapeutic education. Improved understanding of BGL fluctuations. Real-time prediction to predict risks. This allows for greater personalization and better regulation. Manage complex phases of life with rapid glucose changes. Telemedicine & retrospective analysis. Decision-support for patients. Hillo is currently working on the next versions of its AI technology, a therapeutic recommendation system to anticipate and prevent hypoglycemia and hyperglycemia, whose CE mark class IIB is planned for 2020, and the new generation of artificial pancreas(AP) for 2021, which will help overcome the main limitations of current AP systems thanks to the ultra-personalization provided by machine learning. The CE mark class IIB medical device will be the first self-learning artificial intelligence to predict blood glucose levels.